Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2016-09-07 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 1275J' and is dated '07 September 2016'. It is an 'UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY' concerning clinical trial progress and the opening of a new site. The presence of the RNS Number and the nature of the announcement (a corporate update on clinical trials) strongly indicate this is a regulatory news service announcement. Since it is not a full financial report (like 10-K or IR), nor a specific announcement like a dividend (DIV) or director dealing (DIRS), and it is clearly disseminated via the RNS system, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such official, non-standardized announcements.
2016-09-07 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 8466E' and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA', which is a mandatory filing when a major shareholder's stake crosses a threshold. This type of regulatory disclosure regarding changes in significant share ownership perfectly matches the definition for Major Shareholding Notification (MRQ). Although it is an RNS filing, MRQ is the more specific category for TR-1 forms.
2016-07-21 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is identified by the RNS Number (0441D) and the header 'RNS : FOR IMMEDIATE RELEASE'. The content details a TR-1 notification regarding a change in major shareholding interest by Aviva plc in ImmuPharma PLC, specifically noting the acquisition/disposal of voting rights and the resulting percentage (9.22%). This type of regulatory filing, which reports insider or major shareholder transactions, directly corresponds to the definition of Director's Dealing (DIRS) or, more broadly, a notification of change in significant share ownership (MRQ). Since the document explicitly details the change in voting rights and ownership percentage by a major shareholder (Aviva plc), it fits the 'Major Shareholding Notification' (MRQ) category best, as TR-1 forms are the standard mechanism for reporting these changes under relevant regulations. While DIRS covers directors, MRQ covers any major shareholder crossing thresholds. Given the structure and content, MRQ is the most precise fit among the options provided for a major shareholder notification.
2016-07-01 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1179 characters) and contains an RNS Number, indicating it is a regulatory announcement from the London Stock Exchange. The content discusses a 'Second Price Monitoring Extension' for a security, which is a specific operational notice related to trading halts or volatility controls. This type of miscellaneous, non-standard regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory filing category.
2016-06-27 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1162 characters) and contains an 'RNS Number' header, indicating it is a regulatory announcement from the London Stock Exchange. The content discusses a 'Price Monitoring Extension' for an auction call period, which is a specific operational notice related to trading mechanisms, not a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or ER). Since it is a general regulatory announcement that doesn't fit the highly specific categories like DIRS, DIV, or ER, the most appropriate fallback category is Regulatory Filings (RNS).
2016-06-27 English
Appointment of Joint Broker
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 5848B' and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. RNS stands for Regulatory News Service, which is a general regulatory announcement system, often used for immediate, non-standardized disclosures that don't fit into specific SEC forms (like 8-K or 10-K). The content announces the appointment of a joint broker, which is a corporate action announcement. Since there is no specific category for 'Broker Appointment' and it is explicitly marked as an RNS release, the most appropriate classification is the general regulatory announcement fallback category.
2016-06-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.